Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00070954
Status:
TERMINATED
Last Update Posted:
2018-07-18
First Post:
2003-10-09
Brief Title:
Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy ECT
Sponsor:
Medical University of South Carolina
Organization:
Medical University of South Carolina
Study Overview
Official Title:
Ginkgo Biloba for ECT-induced Memory Deficits
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Electroconvulsive therapy ECT is an effective treatment for severe or medication-resistant depression and other psychiatric disorders A common side effect of ECT is problems with short-term memory during treatment This study will test whether taking ginkgo biloba GB prior to and during the course of ECT will lessen the effects of ECT on short-term memory
Detailed Description:
ECT is a safe and effective modern treatment for severe depression and other psychiatric conditions An estimated 100000 treatments occur per year in the United States ECTs most bothersome adverse effect is memory loss with all patients receiving ECT experiencing some degree of short-term cognitive impairment At present there are no known effective pharmacologic treatments to prevent or improve ECT-induced cognitive dysfunction Preliminary research has shown the herbal preparation GB aids cognitive function and memory in both patients with dementia and in normal volunteers This study will investigate the utility and safety of GB to minimize the cognitive impairment typically associated with ECT
Participants in this study will be randomly assigned to receive either twice-daily GB or placebo Participants will begin taking GB or placebo as soon as consent is obtained and baseline testing is completed in order to reach steady-state plasma levels of GB prior to ECT Patients will undergo cognitive testing at specified intervals following ECT The final study visit will occur one week after a participants final ECT treatment
Participants in this study will be randomly assigned to receive either twice-daily GB or placebo Participants will begin taking GB or placebo as soon as consent is obtained and baseline testing is completed in order to reach steady-state plasma levels of GB prior to ECT Patients will undergo cognitive testing at specified intervals following ECT The final study visit will occur one week after a participants final ECT treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R21AT000939-01A1 | NIH | None | httpsreporternihgovquickSearchR21AT000939-01A1 |